Cognition Therapeutics, Inc. is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders.
The company’s candidates work by binding to protein components of the σ-2 (sigma-2) receptor complex, which is present on synapses and acts as a key regulator of cellular damage and stress response. Receptor component proteins (PGRMC1 and TMEM97) control autophagy, cholesterol synthesis and lipid membrane-bound protein trafficking, all of which are associated with age-related central nervous system (CNS) disorders.
Lead Candidate – CT1812
Cognition’s lead candidate, CT1812, is an orally delivered, first-in-class, brain-penetrant small molecule drug designed to bind selectively to the σ-2 receptor complex. By so doing, the aim is to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration (dry AMD), geographic atrophy and other conditions.
The first indication the company is pursuing is mild-to-moderate Alzheimer’s disease.
In this indication, seven clinical trials have been or are being conducted with CT1812 including a planned Phase 2 study anticipated to commence in 2021 in collaboration with the Alzheimer’s Clinical Trial Consortium (ACTC). These studies have been funded in large part by $117.6M in cumulative grants awarded by the National Institute on Aging, part of the NIH.